Bausch + Lomb Raises Full-Year Guidance on Strong Q2 Growth
Event summary
- Bausch + Lomb reported a 9% year-over-year revenue increase in Q2 2026, with total revenue reaching $1.394 billion.
- The company saw double-digit growth in its Surgical and Pharmaceuticals segments, driven by premium intraocular lenses (IOLs) and branded pharmaceuticals like MIEBO and XIIDRA.
- Adjusted EBITDA increased by 26% year-over-year to $241 million, reflecting operating efficiencies and revenue growth.
- Bausch + Lomb raised its full-year 2026 guidance, projecting revenue between $5.440 billion and $5.540 billion, up from the previous range of $5.420 billion to $5.520 billion.
The big picture
Bausch + Lomb's strong Q2 performance and raised guidance reflect its strategic focus on premium product segments and operational efficiencies. The company's ability to leverage these strengths will be crucial in a competitive eye health market, where innovation and regulatory approvals play pivotal roles.
What we're watching
- Premium Product Growth
- The pace at which Bausch + Lomb can sustain growth in its premium IOL portfolio, which now accounts for 13% of total Surgical revenue.
- Pharmaceutical Momentum
- Whether the company can maintain the strong performance of MIEBO and XIIDRA, which delivered a combined 27% revenue growth in the first half of 2026.
- Regulatory Approvals
- The timeline for regulatory approvals following positive topline results from the pivotal clinical study evaluating the enVista Beyond investigational IOL.
Related topics